GLP-1 and metabolic
Gray Market Retatrutide: What the Trial Evidence Can and Cannot Transfer
AM
· 9 min read
A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
On this page · 6 sections
"Gray market retatrutide" means product sold as retatrutide for personal use outside a clinical trial. Retatrutide is an investigational triple agonist in Eli Lilly's phase 3 TRIUMPH programme, and no regulator has approved it. Its trial results, including mean weight change of up to −24.2% at 48 weeks in phase 2, belong to the trial drug: a characterised material, given to screened volunteers under monitoring. A product bearing the same name inherits none of that evidence. The only published human data on such products are case reports and self-reports.

What the trials of retatrutide actually tested
Retatrutide (LY3437943) is a single peptide that activates the GIP, GLP-1 and glucagon receptors. The retatrutide overview covers the pharmacology. The randomised evidence published so far:
| Trial | Population | Comparator | Duration | Reported result for the trial drug |
|---|---|---|---|---|
| Phase 2 (Jastreboff 2023) | 338 adults with obesity, or overweight plus a weight-related condition | Placebo | 48 weeks | Mean weight change −8.7% to −24.2% across the doses studied vs −2.1% |
| TRIUMPH-1 (2026) | 2,339 adults with obesity, without diabetes | Placebo | 80 weeks | −17.6% to −25.0% across doses vs −3.9%; knee pain and sleep apnea events also reduced in subgroups |
| TRIUMPH-2 (2026) | 1,152 adults with obesity and type 2 diabetes | Placebo | 80 weeks | −11.9% to −18.8% across doses vs −5.1% |
The safety findings matter as much as the efficacy. In phase 2, gastrointestinal events were dose-related and mostly mild to moderate. They were partly reduced by starting lower, and heart rate rose in a dose-dependent way, peaking at 24 weeks. In TRIUMPH-2, hypotension and dysesthesia (abnormal skin sensation) were more frequent than on placebo. Permanent discontinuation for adverse events or death reached 12% in one retatrutide arm against 5% on placebo.
ClinicalTrials.gov lists further phase 3 trials still under way. They include a head-to-head comparison with tirzepatide (TRIUMPH-5, NCT06662383), a weight-maintenance trial (TRIUMPH-6, NCT06859268), and a cardiovascular and kidney outcomes trial (NCT06383390). Until those report, nobody knows whether retatrutide reduces or increases cardiovascular events, what happens when it is stopped, or how it compares directly with an approved drug. For the regulatory contrast with tirzepatide, see tirzepatide vs retatrutide.
Why the trial evidence does not transfer to a product with the same name
A trial result is a statement about a specific system: this material, made and released to a documented specification, given in this way, to these screened people, with these exclusions, followed by investigators who can stop treatment when something goes wrong. Change any part of that system and the result no longer describes what you have. Four links break for product sold outside trials.
Identity and amount. The trial drug's identity, content and impurity profile are characterised and controlled lot to lot. A label on another product is a claim. The claim may be accurate, but the trial cannot be the evidence that it is.
Sterility and contaminants. A product meant for administration to people needs sterility and endotoxin control. A chromatographic purity figure does not measure either.
Population. Trial participants were screened. TRIUMPH-2, for example, required diabetes to be on stable treatment before enrolment. People buying outside a trial include exactly those whom trials screen out.
Monitoring. In a trial, rising heart rate, hypotension or persistent vomiting are recorded and acted on. Outside one, they may never be connected to the product at all.
This is a point about evidence, not about any particular supplier. It applies equally to a well-characterised research reagent: confirming that a vial contains the right peptide is an analytical question, and confirming that a drug is safe in people is a clinical one. Answering the first does not answer the second. HPLC and mass spectrometry can establish what a lot contains, and a certificate of analysis reports that measurement for one lot. Neither can turn a reagent into the trial drug.
What has actually been published about non-trial retatrutide
The published literature on retatrutide used outside trials is thin and almost entirely descriptive.
Case reports. Buzzi and Huber described a woman in her mid-20s admitted with five days of persistent nausea, repeated vomiting, loose stools and reduced intake. Tests found no alternative cause, and standard anti-nausea drugs did not help. Only on repeated questioning did she report receiving an unverified product said to contain retatrutide, given in a wellness setting by a self-described life coach with no medical qualification. She had not considered it a medication. Symptoms resolved within a week, and a standard causality score rated the link as probable.
Branine described a man in his mid-30s with type 1 diabetes who developed severe vomiting, diarrhoea, hyperglycaemia, ketonaemia and acute kidney injury shortly after using an online-purchased product marketed as retatrutide. His partner, who used the same preparation, also had gastrointestinal symptoms. A stool culture grew Shigella, and the author states plainly that causation cannot be established. The case does illustrate a specific hazard. Retatrutide has no studied role in type 1 diabetes, and gastrointestinal illness with reduced intake can tip an insulin-dependent person towards ketosis.
Self-reports. Sehgal and colleagues published a cross-sectional study in JAMA Network Open of adverse effects that social media users described while taking non-approved retatrutide. That design captures what people chose to post. It cannot confirm what was in their vials, how much they used, or how often effects occurred among everyone who used it.
Commentary. A JAMA news article by Rubin and a review by Moiz and colleagues describe a growing online market in unapproved incretin drugs and list the risks: contamination, manufacturing impurities and inaccurate amounts. These are expert summaries, not new data.
The closest analytical evidence concerns a different molecule. Ashraf and colleagues made test purchases of semaglutide from illegal online pharmacies selling it without prescription. None of the three prefilled pens ordered arrived, which the authors attribute to non-delivery scams. The three vials that did arrive held 28.56% to 38.69% more semaglutide than labelled, and endotoxin was detected in every sample. That is three samples of a different compound from sellers presenting product as medicine. It says nothing about retatrutide from any given source, but it shows concretely why a label is not evidence.
The limits of observational data
The illustration above is of a health-record study, and that is the kind of evidence most likely to appear next: case series, poison-centre reports, emergency department records and social media analyses. All of them share one blind spot. They record what someone said was taken, not what was in the vial.
- Exposure is unverified. Without testing the actual product, "retatrutide exposure" is a self-report.
- Denominators are missing. A case report shows that something happened once. It cannot say how often.
- Confounding is unavoidable. People using unapproved products often use several at once, alongside diet changes and other drugs.
- Selection is severe. Serious events reach journals, and uneventful use does not.
Such data are good at raising signals, a pattern worth investigating, and poor at sizing risk or establishing cause. Neither a cluster of bad case reports nor a feed of positive testimonials tells you what the controlled trials did. The study design guide covers why.
Regulatory position in Canada
Retatrutide is not authorised by Health Canada for any use. Authorised drugs carry a Drug Identification Number, searchable in the Drug Product Database. Selling a product for human use without authorisation is a separate matter from supplying a reagent for laboratory research. The Canadian peptide rules article sets out the distinction.
NovaEvum supplies retatrutide as a research reagent for laboratory use. It is not the clinical trial drug, the trial results above are not evidence about it, and it is not for use in people or animals.
Supplied here for laboratory use: Retatrutide. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.
Frequently asked questions
Is gray market retatrutide the same as the drug in the trials? Not in any evidential sense. The trial drug was a characterised material given to screened participants under monitoring, and the published results describe that system. A product sold under the same name outside a trial may contain the same peptide, but the trials cannot be the evidence that it does, or that it behaves the same way.
Has retatrutide been approved anywhere? No. Retatrutide is investigational, and no regulator, including Health Canada and the FDA, has approved it for any use. Phase 3 TRIUMPH trials have begun publishing, with further trials, including a cardiovascular and kidney outcomes trial, still under way. A published phase 3 trial is not an authorisation.
What harms have been reported with non-trial retatrutide? Published case reports describe persistent nausea and vomiting needing hospital care, and severe gastrointestinal illness with ketonaemia in a man with type 1 diabetes, where infection was a competing cause. A social media study catalogued self-reported effects. None of these can establish how common harms are, or confirm what the products contained.
Can a certificate of analysis make a product equivalent to the trial drug? No. A certificate reports what one lot contained when tested: identity, and the share of the sample that is the target peptide. It does not establish sterility unless that was tested, and it carries none of the clinical evidence. Analytical identity and clinical evidence answer different questions.
Why can't observational studies settle whether gray market retatrutide is safe? Because they record what users said they took, not what was in the vial. They also lack denominators, suffer heavy selection towards serious cases, and cannot separate one product from the others people use at the same time. They can raise a signal worth investigating, but they cannot size a risk or prove a cause.
Selected Research References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. pubmed.ncbi.nlm.nih.gov/37366315
- Jastreboff AM, et al.; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. 2026. pubmed.ncbi.nlm.nih.gov/42814954
- Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. 2026;408:1455-1472. pubmed.ncbi.nlm.nih.gov/42810372
- Buzzi RM, Huber LC. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ Case Reports. 2026;19(10):e276106. pubmed.ncbi.nlm.nih.gov/42843917
- Branine N. Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis. Cureus. 2026;18(8):e115260. pubmed.ncbi.nlm.nih.gov/42669023
- Sehgal NKR, Tronieri JS, Rader B, Ungar L, Guntuku SC. Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide. JAMA Network Open. 2026;9(10):e2638929. pubmed.ncbi.nlm.nih.gov/42873503
- Rubin R. Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain. JAMA. 2026. pubmed.ncbi.nlm.nih.gov/42853576
- Moiz A, O'Keefe EL, O'Keefe JH. Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs. Missouri Medicine. 2026;123(4):337-343. pubmed.ncbi.nlm.nih.gov/42757290
- Ashraf AR, Mackey TK, Vida RG, et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of Medical Internet Research. 2024;26:e65440. pubmed.ncbi.nlm.nih.gov/39509151
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
